| Business Summary | | Genzyme
Biosurgery
is
the
operating
division
of
Genzyme
Corporation
that
develops
and
markets
instruments,
devices,
biomaterials
and
biotherapeutic
products
to
improve
or
replace
surgery,
with
an
emphasis
on
orthopaedics
and
cardiothoracics
markets.
It
is
organized
into
three
business
units:
Orthopaedics,
Cardiothoracic
and
Biosurgical
Specialties.
Its
product
and
development
program
portfolio
consists
of
biomaterials,
biotherapeutics,
traditional
devices
and
surgical
closures,
as
well
as
advanced
devices
for
minimally
invasive
cardiovascular
surgery.
Genzyme
Biosurgery's
sales
force
markets
products
directly
to
surgeons
and
hospital
administrators
throughout
the
United
States
and
Europe.
It
also
uses
a
network
of
distributors
to
sell
products
in
Europe,
Asia
and
Latin
America. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GZBX
is
engaged
in
the
manufacturer,
development
and
marketing
of
biotechnology
products
that
attempt
to
improve
and/or
replace
surgery
by
growing
tissues
and
organs
in
vitro
for
implantation
to
replace
diseased
or
aged
body
parts.
For
the
six
months
ended
6/30/01,
revenues
increased
61%
to
$114.5
million.
Net
loss
totaled
$72.9
million,
up
from
$29.4
million.
Revenues
reflect
growth
in
sales
of
Carticel
chondrocytes.
Net
loss
reflects
increased
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Henri Termeer, 55 Chairman,
CEO | $1.9M | Earl Collier, Jr., 53 Pres | 814K | Michael Wyzga, 46 CFO,
Sr. VP | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|